Table 2 Clinical features, laboratory characteristics, and outcome of ALL in relation to ETP subtype

Age

Median (range)

13 (4–18)

6 (1–18)

0.013

WBC (× 10⁹/L)

Median (range)

12.9 (3.2–100)

240 (1.7–967)

0.001

Hemoglobin (g/dl)

Median (range)

8.7 (5.9–14.4)

7.6 (4–14.5)

0.248

Platelet count (× 10⁹/L)

Median (range)

64 (8–224)

46 (9–693)

0.306

PB blast (%)

Median (range)

50 (0–85)

85 (0–99)

0.037

BM blast (%)

Median (range)

88 (28–92)

90 (0–99)

0.230

Gender

Male

5 (71.4%)

39 (69.6)

0.923

Female

2 (28.6%)

17 (30.4)

CD34

Negative

5 (71.4)

48 (85.7)

0.306

Positive

2 (28.6)

8 (14.3)

Cytogenetics

Normal

1 (14.3)

19 (33.9)

0.415

Abnormal

6 (85.7)

37 (66.1)

MCN

Diploid

2 (28.6)

44 (78.6)

0.009

Hypodiploid

4 (57.1)

7 (12.5)

Hyperdiploid

1 (14.3)

5 (8.9)

Complex karyotypes

Negative

4 (57.1)

49 (87.5)

0.073

Positive

3 (42.9)

7 (12.5)

TCRA/D translocations

Negative

5 (71.4)

38 (67.9)

0.848

Positive

2 (28.6)

18 (32.1)

TCRA/D deletions

Negative

6 (85.7)

54 (96.4)

0.302

Positive

1 (14.3)

2 (3.6)

TCRA/D amplifications

Negative

3 (42.9)

49 (87.5)

0.014

Positive

4 (57.1)

7 (12.5)

Total TCRA/D abnormalities

Negative

1 (14.3)

32 (57.1)

0.047

Positive

6 (85.7)

24(42.9)

TCRβ

Negative

5 (71.4)

45 (80.4)

0.627

Positive

2 (28.6)

11 (19.6)

MRD15

 < 0.01

0 (0)

10 (21.7)

0.363

 ≥ 0.01

3 (100)

33 (78.3)

 < 0.1

0 (0)

16 (37.2)

0.542

 ≥ 0.1

3 (100)

27 (62.8)

MRD42

 < 0.01

1 (25.0)

14 (36.8)

0.638

 ≥ 0.01

3 (75.0)

24 (63.2)

 < 0.1

2 (50)

27 (71.1)

0.576

 ≥ 0.1

2 (50)

11 (28.9)

Relapse

Negative

6 (85.7%)

49 (87.5%)

0.894

Positive

1 (14.3%)

7 (12.5%)

Early death

Negative

5 (71.4%)

47 (83.9%)

0.595

Positive

2 (28.6%)

9 (16.1%)

Death

Negative

2 (28.6%)

34 (60.7%)

0.128

Positive

5 (71.4%)

22 (39.3%)